1. Home
  2. APRE vs SYNX Comparison

APRE vs SYNX Comparison

Compare APRE & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.23

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

N/A

Current Price

$0.66

Market Cap

6.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
APRE
SYNX
Founded
2006
2005
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
6.0M
IPO Year
2019
2023

Fundamental Metrics

Financial Performance
Metric
APRE
SYNX
Price
$0.23
$0.66
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $3.30
N/A
AVG Volume (30 Days)
★ 133.5K
16.7K
Earning Date
11-04-2026
08-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.22
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.65
52 Week High
$1.49
$1.95

Technical Indicators

Market Signals
Indicator
APRE
SYNX
Relative Strength Index (RSI) 26.17 34.05
Support Level N/A $0.65
Resistance Level $0.81 $1.08
Average True Range (ATR) 0.06 0.06
MACD -0.01 -0.02
Stochastic Oscillator 8.91 3.49

Price Performance

Historical Comparison
APRE
SYNX

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.

Share on Social Networks: